Evidence-based management of infertile couples with repeated implantation failure following IVF

Current Women's Health Reviews

Volumn 6, Issue 3, 2010, Pages 200-218

  Ly, Kim D ^a   Aziz, Nabil ^b   Safi, Joelle ^a   Agarwal, Ashok ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b LIVERPOOL WOMEN S HOSPITAL   (United Kingdom)

Author keywords

Assisted hatching; Blastocyst transfer; Endometrial receptivity; Hysteroscopy; In vitro fertilization; Repeat implantation failure; Salpingectomy

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; PHOSPHOLIPID ANTIBODY; SILDENAFIL; TUMOR NECROSIS FACTOR ALPHA;

ALLOGENIC LYMPHOCYTE THERAPY; ARTICLE; CHROMOSOME ABERRATION; COCULTURE; EMBRYO TRANSFER; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC SCREENING; HATCHING; HUMAN; HYDROSALPINX; HYSTEROSCOPY; IMMUNOTHERAPY; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; MALE INFERTILITY; NATURAL KILLER CELL; NIDATION; NONHUMAN; OOCYTE DONATION; PRACTICE GUIDELINE; PREGNANCY DISORDER; PREGNANCY OUTCOME; PREGNANCY RATE; PRIORITY JOURNAL; SALPINGECTOMY; SCORING SYSTEM; TH2 CELL; UTERINE TUBE DISEASE;

EID: 78649305091     PISSN: 15734048     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340410792007073     Document Type: Article

References (229)

1. Weissman A, Biran G, Nahum H, Glezerman M, Levran D.Blastocyst culture and transfer: lessons from an unselected,difficult IVF population. Reprod Biomed Online 2008; 17(2): 220-8.
2. Martin-Johnston MK, Uhler ML, Grotjan HE, Lifchez AS, NaniJM, Beltsos AN. Lower chance of pregnancy with repeated cycleswith in vitro fertilization. J Reprod Med 2009; 54(2): 67-72.
3. Ola, Bolarinde; Li, Tin-Chiu Implantation failure following in-vitrofertilization. Curr Opin Obstet Gynecol 2006; 18(4): 440-5.
4. Achache H, Tsafrir A, Prus D, Reich R, Revel A. Defective endo-metrial prostaglandin synthesis identified in patients with repeatedimplantation failure undergoing in vitro fertilization. Fertil Steril 2009. [Epub ahead of print]
5. Koler M, Achache H, Tsafrir A, Smith Y, Revel A, Reich R. Dis-rupted gene pattern in patients with repeated in vitro fertilization(IVF) failure. Hum Reprod 2009; 24(10): 2541-8.
6. Bersinger NA, Wunder DM, Birkhäuser MH, Mueller MD.Gene expression in cultured endometrium from women with differ-ent outcomes following IVF. Mol Hum Reprod 2008; 14(8): 475-84.
7. Cline AM, Kutteh WH. Is there a role of autoimmunity in implanta-tion failure after in-vitro fertilization? Curr Opin Obstet Gynecol 2009; 21(3): 291-5.
8. Milki AA, Hinckley MD, Fisch JD, Dasig D, Behr B. Comparisonof blastocyst transfer with day 3 embryo transfer in similar patientpopulations. Fertil Steril 2000; 73(1): 126-9.
9. Wilson M, Hartke K, Kiehl M, Rodgers J, Brabec C, Lyles R. Inte-gration of blastocyst transfer for all patients. Fertil Steril 2002; 77(4): 693-6.
10. Levron J, Shulman A, Bider D, Seidman D, Levin T, Dor J. Aprospective randomized study comparing day 3 with blastocyst-stage embryo transfer. Fertil Steril 2002; 77(6): 1300-1.
11. Papanikolaou EG, D'haeseleer E, Verheyen G, et al. Live birth rateis significantly higher after blastocyst transfer than after cleavage-stage embryo transfer when at least four embryos are available onday 3 of embryo culture. A randomized prospective study. HumReprod 2005; 20(11): 3198-203.
12. Shapiro BS, Richter KS, Harris DC, Daneshmand ST. Dramaticdeclines in implantation and pregnancy rates in patients who un-dergo repeated cycles of in vitro fertilization with blastocyst trans-fer after one or more failed attempts. Fertil Steril 2001; 76(3): 538-42.
13. Cruz JR, Dubey AK, Patel J, Peak D, Hartog B, Gindoff PR.Isblastocyst transfer useful as an alternative treatment for patientswith multiple in vitro fertilization failures? Fertil Steril 1999; 72(2): 218-20.
14. Levitas E, Lunenfeld E, Har-Vardi I, et al. Blastocyst-stage embryotransfer in patients who failed to conceive in three or more day 2-3embryo transfer cycles: a prospective, randomized study. FertilSteril 2004; 81(3): 567-71.
15. Barrenetxea G, López de Larruzea A, Ganzabal T, Jiménez R, Carbonero K, Mandiola M. Blastocyst culture after repeated failureof cleavage-stage embryo transfers: a comparison of day 5 and day6 transfers. Fertil Steril 2005; 83(1): 49-53.
16. Gabrielsen A, Agerholm I, Toft B, et al. Assisted hatching im-proves implantation rates on cryopreserved-thawed embryos. Arandomized prospective study. Hum Reprod 2004; 19(10): 2258-62.
17. Germond M, Primi MP, Senn A. Hatching: how to select the clini-cal indications. Ann N Y Acad Sci 2004; 1034: 145-51.
18. Sheen TC, Chen SR, Au HK, Chien YY, Wu KY, Tzeng CR.Herniated blastomere following chemically assisted hatching mayresult in monozygotic twins. Fertil Steril 2001; 75(2): 442-4.
19. Das S, Blake D, Farquhar C, Seif MM. Assisted hatching onassisted conception (IVF and ICSI). Cochrane Database Syst Rev 2009; (2): CD001894.
20. Simón C, Mercader A, Garcia-Velasco J, et al. Coculture of humanembryos with autologous human endometrial epithelial cells inpatients with implantation failure. J Clin Endocrinol Metab 1999; 84(8): 2638-46.
21. Carrell DT, Peterson CM, Jones KP, et al. A simplified coculturesystem using homologous, attached cumulus tissue results in im-proved human embryo morphology and pregnancy rates during invitro fertilization. J Assist Reprod Genet 1999; 16(7): 344-9.
22. Fabbri R, Porcu E, Marsella T, et al. Human embryo developmentand pregnancies in an homologous granulosa cell coculture system. J Assist Reprod Genet 2000; 17(1): 1-12.
23. Dirnfeld M, Goldman S, Gonen Y, Koifman M, Calderon I, Abramovici H. A simplified coculture system with luteinizedgranulosa cells improves embryo quality and implantation rates: acontrolled study. Fertil Steril 1997; 67(1): 120-2.
24. Escribá MJ, Escobedo-Lucea C, Mercader A, de los Santos MJ, Pellicer A, Remohí J. Ultrastructure of preimplantation geneticdiagnosis-derived human blastocysts grown in a coculture systemafter vitrification. Fertil Steril 2006; 86(3): 664-71.
25. Bongso A, Ng SC, Ratnam S. Co-cultures: their relevance to as-sisted reproduction. Hum Reprod 1990; 5(8): 893-900.
26. Bongso A, Soon-Chye N, Sathananthan H, Lian NP, Rauff M, Ratnam S. alImproved quality of human embryos when co-culturedwith human ampullary cells. Hum Reprod 1989; 4(6): 706-13.
27. Morgan K, Wiemer K, Steuerwald N, Hoffman D, Maxson W, Godke R. Use of videocinematography to assess morphologicalqualities of conventionally cultured and cocultured embryos. HumReprod 1995; 10(9): 2371-6.
28. Magli MC, Gianaroli L, Ferraretti AP, Fortini D, Fiorentino A, D'Errico A. Human embryo co-culture: results of a randomizedprospective study. Int J Fertil Menopausal Stud 1995; 40(5): 254-9.
29. Tucker MJ, Morton PC, Wright G, et al. Enhancement of outcomefrom intracytoplasmic sperm injection: does co-culture or assistedhatching improve implantation rates? Hum Reprod 1996; 11(11):2434-7.
30. Wiemer KE, Garrisi J, Steuerwald N, et al. Beneficial aspects ofco-culture with assisted hatching when applied to multiple-failurein-vitro fertilization patients. Hum Reprod 1996; 11(11): 2429-33.
31. Wiemer KE, Cohen J, Amborski GF, et al. In-vitro developmentand implantation of human embryos following culture on fetal bo-vine uterine fibroblast cells. Hum Reprod 1989; 4(5): 595-600.
32. Wiemer KE, Cohen J, Wiker SR, Malter HE, Wright G, Godke RA. Coculture of human zygotes on fetal bovine uterine fibroblasts:embryonic morphology and implantation. Fertil Steril 1989; 52(3):503-8.
33. Van Blerkom J. Development of human embryos to the hatchedblastocyst stage in the presence or absence of a monolayer of Verocells. Hum Reprod 1993; 8(9): 1525-39.
34. Sakkas D, Jaquenoud N, Leppens G, Campana A. Comparison ofresults after in vitro fertilized human embryos are cultured in rou-tine medium and in coculture on Vero cells: a randomized study. Fertil Steril 1994; 61(3): 521-5.
35. Turner K, Lenton EA. The influence of Vero cell culture on humanembryo development and chorionic gonadotrophin production invitro. Hum Reprod 1996; 11(9): 1966-74.
36. Ben-Chetrit A, Jurisicova A, Casper RF. Coculture with ovariancancer cell enhances human blastocyst formation in vitro. FertilSteril 1996; 65(3): 664-6.
37. Hu Y, Maxson W, Hoffman D, et al. Co-culture with assistedhatching of human embryos using Buffalo rat liver cells. Hum Re-prod 1998; 13(1): 165-8.
38. Wetzels AM, Bastiaans BA, Hendriks JC, et al. The effects of co-culture with human fibroblasts on human embryo development invitro and implantation. Hum Reprod 1998; 13(5): 1325-30.
39. Kattal N, Cohen J, Barmat LI. Role of coculture in human in vitrofertilization: a meta-analysis. Fertil Steril 2008; 90(4): 1069-76.
40. Weichselbaum A, Paltieli Y, Philosoph R, et al. Improved devel-opment of very-poor-quality human preembryos by coculture withhuman fallopian ampullary cells. J Assist Reprod Genet 2002; 19(1): 7-13.
41. Eyheremendy V, Raffo FG, Papayannis M, Barnes J, Granados C, Blaquier J. Beneficial effect of autologous endometrial cell cocul-ture in patients with repeated implantation failure. Fertil Steril 2010; 93(3): 769-73
42. Desai N, Abdelhafez F, Bedaiwy MA, Goldfarb J. Live births inpoor prognosis IVF patients using a novel non-contact human en-dometrial co-culture system. Reprod Biomed Online 2008; 16(6):869-74.
43. Richter KS. The importance of growth factors for preimplantationembryo development and in-vitro culture. Curr Opin Obstet Gyne-col 2008; 20(3): 292-304.
44. d'Estaing SG, Lornage J, Hadj S, Boulieu D, Salle B, Guérin JF.Comparison of two blastocyst culture systems: coculture on Verocells and sequential media. Fertil Steril 2001; 76(5): 1032-5.
45. Griffin DK. The incidence, origin, and etiology of aneuploidy. IntRev Cytol 1996; 167: 263-96.
46. Maroulis GB, Koutlaki N. Preimplantation genetic diagnosis. AnnN Y Acad Sci 2006; 1092: 279-84.
47. Farfalli VI, Magli MC, Ferraretti AP, Gianaroli L.Role of ane-uploidy on embryo implantation. Gynecol Obstet Invest 2007; 64(3): 161-5.
48. Fragouli E, Katz-Jaffe M, Alfarawati S, et al. Comprehensivechromosome screening of polar bodies and blastocysts fromcouples experiencing repeated implantation failure. Fertil Steril 2009. [Epub ahead of print]
49. Raziel A, Friedler S, Schachter M, Kasterstein E, Strassburger D, Ron-El R. Increased frequency of female partner chromosomalabnormalities in patients with high-order implantation failure afterin vitro fertilization. Fertil Steril 2002; 78(3): 515-9.
50. Gianaroli L, Magli MC, Munné S, Fiorentino A, Montanaro N, Ferraretti AP. Will preimplantation genetic diagnosis assist patientswith a poor prognosis to achieve pregnancy? Hum Reprod 1997; 12(8): 1762-7.
51. Pehlivan T, Rubio C, Rodrigo L, et al. Impact of preimplantationgenetic diagnosis on IVF outcome in implantation failure patients. Reprod Biomed Online 2003; 6(2): 232-7.
52. ESHRE PGD Consortium Steering Committee. ESHRE Preimplan-tation Genetic Diagnosis Consortium: data collection III (May2001). Hum Reprod 2002; 17(1): 233-46.
53. Gianaroli L, Magli MC, Ferraretti AP, Munné S. Preimplantationdiagnosis for aneuploidies in patients undergoing in vitro fertiliza-tion with a poor prognosis: identification of the categories forwhich it should be proposed. Fertil Steril 1999; 72(5): 837-44.
54. Goossens V, Harton G, Moutou C, Traeger-Synodinos J, Van Rij M, Harper JC. ESHRE PGD Consortium data collection IX: cyclesfrom January to December 2006 with pregnancy follow-up to Oc-tober 2007. Hum Reprod 2009; 24(8): 1786-810.
55. Platteau P, Staessen C, Michiels A, Van Steirteghem A, Liebaers I, Devroey P. Which patients with recurrent implantation failure afterIVF benefit from PGD for aneuploidy screening? Reprod BiomedOnline 2006; 12(3): 334-9.
56. Mantzouratou A, Mania A, Fragouli E, et al. Variable aneuploidymechanisms in embryos from couples with poor reproductive histo-ries undergoing preimplantation genetic screening. Hum Reprod 2007; 22(7): p. 1844-53.
57. Voullaire L, Wilton L, McBain J, Callaghan T, Williamson R. Chromosome abnormalities identified by comparative genomic hy-bridization in embryos from women with repeated implantationfailure. Mol Hum Reprod 2002; 8(11): 1035-41.
58. Braude P, Bolton V, Moore S. Human gene expression first occursbetween the four- and eight-cell stages of preimplantation devel-opment. Nature 1988; 332(6163): 459-61.
59. Wells D, Bermudez MG, Steuerwald N, et al. Expression of genesregulating chromosome segregation, the cell cycle and apoptosisduring human preimplantation development. Hum Reprod 2005; 20(5): 1339-48.
60. Voullaire L, Collins V, Callaghan T, McBain J, Williamson R, Wilton L. High incidence of complex chromosome abnormality incleavage embryos from patients with repeated implantation failure. Fertil Steril 2007; 87(5): 1053-8.
61. Margalioth EJ, Ben-Chetrit A, Gal M, Eldar-Geva T. Investigationand treatment of repeated implantation failure following IVF-ET. Hum Reprod 2006; 21(12): 3036-43.
62. Munné S, Magli C, Bahçe M, et al. Preimplantation diagnosis ofthe aneuploidies most commonly found in spontaneous abortionsand live births: XY, 13, 14, 15, 16, 18, 21, 22. Prenat Diagn 1998; 18(13): 1459-66.
63. Kahraman S, Bahçe M, Samli H, et al. Healthy births and ongoingpregnancies obtained by preimplantation genetic diagnosis in pa-tients with advanced maternal age and recurrent implantation failure. Hum Reprod 2000; 15(9): 2003-7.
64. Munné S, Sandalinas M, Escudero T, et al. Improved implantationafter preimplantation genetic diagnosis of aneuploidy. Reprod Bio-med Online 2003; 7(1): 91-7.
65. Arefi S, Soltanghoraei H, Sadeghi MR, Tabaei AS, Zeraati H, Zarnani H. Findings on hysteroscopy in patients with in vitro fer-tilization by intra cytoplasmic single sperm injection and embryotransfer failures. Saudi Med J 2008; 29(8): 1201-2.
66. Lorusso F, Ceci O, Bettocchi S, et al. Office hysteroscopy in an invitro fertilization program. Gynecol Endocrinol 2008; 24(8): 465-9.
67. Oliveira FG, Abdelmassih VG, Diamond MP, et al. Uterine cavityfindings and hysteroscopic interventions in patients undergoing invitro fertilization-embryo transfer who repeatedly cannot conceive. Fertil Steril 2003; 80(6): 1371-5.
68. Makrakis E, Hassiakos D, Stathis D, Vaxevanoglou T, Orfanoudaki E, Pantos K. Hysteroscopy in women with implantation failures af-ter in vitro fertilization: findings and effect on subsequent preg-nancy rates. J Minim Invasive Gynecol 2009; 16(2): 181-7.
69. Madani T, Ghaffari F, Kiani K, Hosseini F. Hysteroscopic polypec-tomy without cycle cancellation in IVF cycles. Reprod Biomed On-line 2009; 18(3):412-5.
70. Küçük T, Safali M. Chromohysteroscopy for evaluation of en-dometrium in recurrent in vitro fertilization failure. J Assist ReprodGenet 2008; 25(2-3): 79-82.
71. Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally activetype 5 cyclic GMP-specific phosphodiesterase inhibitor for thetreatment of penile erectile dysfunction. Int J Impot Res 1996; 8(2):47-52.
72. Goodman C, Jeyendran RS, Coulam CB. Coulam, P53 tumor sup-pressor factor, plasminogen activator inhibitor, and vascular endo-thelial growth factor gene polymorphisms and recurrent implanta-tion failure. Fertil Steril 2009; 92(2): 494-8.
73. Sher G, Fisch JD. Vaginal sildenafil (Viagra): a preliminary reportof a novel method to improve uterine artery blood flow and endo-metrial development in patients undergoing IVF. Hum Reprod 2000; 15(4): 806-9.
74. Sher G, Fisch JD. Effect of vaginal sildenafil on the outcome of invitro fertilization (IVF) after multiple IVF failures attributed topoor endometrial development. Fertil Steril 2002; 78(5): 1073-6.
75. Check JH, Graziano V. Multiple confounders--measured witherror? Fertil Steril 2003; 79(5): 1256-7; author reply 1257-8.
76. Zinger M, Liu JH, Thomas MA. Successful use of vaginal silde-nafil citrate in two infertility patients with Asherman's syndrome. JWomens Health (Larchmt) 2006; 15(4): 442-4.
77. Paulus WE, Strehler E, Zhang M, Jelinkova L, El-Danasouri I, Sterzik K. Benefit of vaginal sildenafil citrate in assisted reproduc-tion therapy. Fertil Steril 2002; 77(4): 846-7.
78. Quenby S, Bates M, Doig T, et al. Pre-implantation endometrialleukocytes in women with recurrent miscarriage. Hum Reprod 1999; 14(9): 2386-91.
79. Gilman-Sachs A, DuChateau BK, Aslakson CJ, et al. Natural killer(NK) cell subsets and NK cell cytotoxicity in women with historiesof recurrent spontaneous abortions. Am J Reprod Immunol 1999; 41(1): 99-105.
80. Aoki K, Kajiura S, Matsumoto Y, et al. Preconceptional natural-killer-cell activity as a predictor of miscarriage. Lancet 1995; 345(8961): 1340-2.
81. Strandell A, Lindhard A, Waldenström U, Thorburn J. Nitric oxideinhibits development of embryos and implantation in mice. MolHum Reprod 1998; 4(5): 503-7.
82. Battaglia C, Ciotti P, Notarangelo L, Fratto R, Facchinetti F, deAloysio D. Embryonic production of nitric oxide and its role in im-plantation: a pilot study. J Assist Reprod Genet 2003; 20(11): 449-54.
83. Strandell A, Waldenström U, Nilsson L, Hamberger L. Hydrosal-pinx reduces in-vitro fertilization/embryo transfer pregnancy rates. Hum Reprod 1994; 9(5): 861-3.
84. Bontis JN, Dinas KD. Management of hydrosalpinx: reconstructivesurgery or IVF? Ann N Y Acad Sci 2000; 900: 260-71.
85. Strandell A, Lindhard A, Waldenström U, Thorburn J. Hydrosal-pinx and IVF outcome: cumulative results after salpingectomy in arandomized controlled trial. Hum Reprod 2001; 16(11): 2403-10.
86. Mansour R, Aboulghar M, Serour GI. Controversies in the surgicalmanagement of hydrosalpinx. Curr Opin Obstet Gynecol 2000; 12(4): 297-301.
87. Granot I, Dekel N, Segal I, Fieldust S, Shoham Z, Barash A. Ishydrosalpinx fluid cytotoxic? Hum Reprod 1998; 13(6): 1620-4.
88. Sharara FI. The role of hydrosalpinx in IVF: simply mechanical? Hum Reprod 1999; 14(3): 577-8.
89. Seli E, Kayisli UA, Cakmak H, et al. Removal of hydrosalpingesincreases endometrial leukaemia inhibitory factor (LIF) expressionat the time of the implantation window. Hum Reprod 2005; 20(11):3012-7.
90. Bildirici I, Bukulmez O, Ensari A, Yarali H, Gurgan T. A prospec-tive evaluation of the effect of salpingectomy on endometrial re-ceptivity in cases of women with communicating hydrosalpinges. Hum Reprod 2001; 16(11): 2422-6.
91. Meyer WR, Lessey BA, Castelbaum AJ. Hydrosalpinx and altereduterine receptivity. Fertil Steril 1997; 68(5): 944-5.
92. Grifo JA, Jeremias J, Ledger WJ, Witkin SS. Interferon-gamma inthe diagnosis and pathogenesis of pelvic inflammatory disease. AmJ Obstet Gynecol 1989; 160(1): 26-31.
93. Ben-Rafael Z, Orvieto R. Cytokines--involvement in reproduction. Fertil Steril 1992; 58(6): 1093-9.
94. Jones RB, Mammel JB, Shepard MK, Fisher RR. Recovery ofChlamydia trachomatis from the endometrium of women at risk forchlamydial infection. Am J Obstet Gynecol 1986; 155(1): 35-9.
95. Lass A. What effect does hydrosalpinx have on assisted reproduc-tion? What is the preferred treatment for hydrosalpines? Theovary's perspective. Hum Reprod 1999; 14(7): 1674-7.
96. Dechaud H, Anahory T, Aligier N, Arnal F, Humeau H, Hedon B. Salpingectomy for repeated embryo nonimplantation after in vitrofertilization in patients with severe tubal factor infertility. J AssistReprod Genet 2000; 17(4): 200-6.
97. Johnson NP, Mak W, Sowter MC. Surgical treatment for tubaldisease in women due to undergo in vitro fertilisation. CochraneDatabase Syst Rev 2004; (3): CD002125.
98. Johnson NP, Mak W, Sowter MC. Laparoscopic salpingectomy forwomen with hydrosalpinges enhances the success of IVF: a Coch-rane review. Hum Reprod 2002; 17(3): 543-8.
99. Practice Committee of American Society for Reproductive Medi-cine; Practice Committee of Society for Assisted ReproductiveTechnology. Fertil Steril 2008; 90(5 Suppl): S30-44.
100. Klein J, Sauer MV. Oocyte donation. Best Pract Res Clin ObstetGynaecol 2002; 16(3): 277-91.
101. Sauer MV, Kavic SM. Oocyte and embryo donation 2006: review-ing two decades of innovation and controversy. Reprod BiomedOnline 2006; 12(2): 153-62.
102. Lee RM, Silver RM. Recurrent pregnancy loss: summary and clini-cal recommendations. Semin Reprod Med 2000; 18(4): 433-40.
103. Lee RM, Silver RM. The efficacy and safety of human oocytevitrification. Semin Reprod Med 2009; 27(6): 450-5.
104. ASRM Practice Committee response to Rybak and Lieman: elec-tive self-donation of oocytes. Fertil Steril 2009; 92(5): 1513-4.
105. Rienzi L, Romano S, Albricci L, et al. Embryo development offresh 'versus' vitrified metaphase II oocytes after ICSI: a prospec-tive randomized sibling-oocyte study. Hum Reprod 2010; 25(1):66-73.
106. Azem F, Yaron Y, Amit A, et al. Transfer of six or more embryosimproves success rates in patients with repeated in vitro fertiliza-tion failures. Fertil Steril 1995; 63(5): 1043-6.
107. Hu Y, Maxson WS, Hoffman DI, et al. Maximizing pregnancyrates and limiting higher-order multiple conceptions by determin-ing the optimal number of embryos to transfer based on quality. Fertil Steril 1998; 69(4): 650-7.
108. Stern JE, Cedars MI, Jain T, et al. Assisted reproductive technol-ogy practice patterns and the impact of embryo transfer guidelinesin the United States. Fertil Steril 2007; 88(2): 275-82.
109. Campbell B, Erickson L. The number of embryos to transfer: cur-rent practices in Minnesota. Minn Med 2009; 92(4): 40-1.
110. Guidelines on number of embryos transferred. Fertil Steril 2009; 92(5): 1518-9.
111. Guidelines for the number of embryos to transfer following in vitrofertilization No. 182, September 2006. Int J Gynaecol Obstet 2008; 102(2): 203-16.
112. Pandian Z, Bhattacharya S, Ozturk O, Serour G, Templeton A. Number of embryos for transfer following in-vitro fertilisation orintra-cytoplasmic sperm injection. Cochrane Database Syst Rev 2009(2): CD003416.
113. Embryo transfer: tech-niques and variables affecting success. Fertil Steril 2001; 76(5):863-70.
114. Levran D, Farhi J, Nahum H, Royburt M, Glezerman M, Weissman A. Prospective evaluation of blastocyst stage transfer vs. zygote in-trafallopian tube transfer in patients with repeated implantationfailure. Fertil Steril 2002; 77(5): 971-7.
115. Levran D, Mashiach S, Dor J, Levron J, Farhi J. Zygote intrafallo-pian transfer may improve pregnancy rate in patients with repeatedfailure of implantation. Fertil Steril 1998; 69(1): 26-30.
116. Urman B, Yakin K, Balaban B. Recurrent implantation failure inassisted reproduction: how to counsel and manage. B. Treatmentoptions that have not been proven to benefit the couple. ReprodBiomed Online 2005; 11(3): 382-91.
117. Jansen RP. Endocrine response in the fallopian tube. Endocr Rev 1984; 5(4): 525-51.
118. Devroey P, Staessen C, Camus M, De Grauwe E, Wisanto A, Van Steirteghem AC. Zygote intrafallopian transfer as a successfultreatment for unexplained infertility. Fertil Steril 1989; 52(2): 246-9.
119. Hammitt DG, Syrop CH, Hahn SJ, Walker DL, Butkowski CR, Donovan JF. Comparison of concurrent pregnancy rates for in-vitrofertilization--embryo transfer, pronuclear stage embryo transfer andgamete intra-fallopian transfer. Hum Reprod 1990; 5(8): 947-54.
120. Asch RH.Uterine versus tubal embryo transfer in the human. Comparative analysis of implantation, pregnancy, and live-birth rates. Ann N Y Acad Sci 1991; 626: 461-6.
121. Farhi J, Weissman A, Nahum H, Levran D. Zygote intrafallopiantransfer in patients with tubal factor infertility after repeated failureof implantation with in vitro fertilization-embryo transfer. FertilSteril 2000; 74(2): 390-3.
122. Habana AE, Palter SF. Is tubal embryo transfer of any value? Ameta-analysis and comparison with the Society for Assisted Repro-ductive Technology database. Fertil Steril 2001; 76(2): 286-93.
123. Aslan D, Elizur SE, Levron J, et al. Comparison of zygote intrafal-lopian tube transfer and transcervical uterine embryo transfer in pa-tients with repeated implantation failure. Eur J Obstet Gynecol Re-prod Biol 2005; 122(2): 191-4.
124. Weissman A, Eldar I, Ravhon A, et al. Timing intra-Fallopiantransfer procedures. Reprod Biomed Online 2007; 15(4): 445-50.
125. Weissman A, F.J., Levran D. Zygote intrafallopian transfer. Reproductive Techniques: Laboratory and Clinical Perspectives, 2nd ed. W.A. Gardner DK, Howies CM, Shoham Z, Eds. LondonTaylor and Francis 2004; pp. 735-48.
126. Ubaldi F, Rienzi L, Ferrero S, et al. Natural in vitro fertilizationcycles. Ann N Y Acad Sci 2004; 1034: 245-51.
127. Morgia F, Sbracia M, Schimberni M, et al. A controlled trial ofnatural cycle versus microdose gonadotropin-releasing hormoneanalog flare cycles in poor responders undergoing in vitro fertiliza-tion. Fertil Steril 2004; 81(6): 1542-7.
128. Bassil S, Godin PA, Donnez J. Outcome of in-vitro fertilizationthrough natural cycles in poor responders. Hum Reprod 1999; 14(5): 1262-5.
129. Schimberni M, Morgia F, Colabianchi J, et al. Natural-cycle invitro fertilization in poor responder patients: a survey of 500 con-secutive cycles. Fertil Steril 2009; 92(4): 1297-301.
130. Pelinck MJ, Hoek A, Simons AH, Heineman MJ. Efficacy of natu-ral cycle IVF: a review of the literature. Hum Reprod Update 2002; 8(2): 129-39.
131. Paria BC, Lim H, Das SK, Reese J, Dey SK. Molecular signaling inuterine receptivity for implantation. Semin Cell Dev Biol 2000; 11(2): 67-76.
132. Paria BC, Lim H, Das SK, Reese J, Dey SK. Time of implantationof the conceptus and loss of pregnancy. N Engl J Med 1999; 340(23): 1796-9.
133. Martín J, Domínguez F, Avila S, et al. Human endometrial recep-tivity: gene regulation. J Reprod Immunol 2002; 55(1-2): 131-9.
134. Davis GE, Senger DR. Endothelial extracellular matrix: biosynthe-sis, remodeling, and functions during vascular morphogenesis andneovessel stabilization. Circ Res 2005; 97(11): 1093-107.
135. Bischof P, Campana A. Molecular mediators of implantation. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14(5): 801-14.
136. Basir GS, O WS, Ng EH, Ho PC. Morphometric analysis of peri-implantation endometrium in patients having excessively highoestradiol concentrations after ovarian stimulation. Hum Reprod 2001; 16(3): 435-40.
137. Devroey P, Bourgain C, Macklon NS, Fauser BC. Reproductivebiology and IVF: ovarian stimulation and endometrial receptivity. Trends Endocrinol Metab 2004; 15(2): 84-90.
138. Tavaniotou A, Albano C, Smitz J, Devroey P. Impact of ovarianstimulation on corpus luteum function and embryonic implantation. J Reprod Immunol 2002; 55(1-2): 123-30.
139. Basille C, Fay S, Hesters L, Frydman N, Frydman R. In vitro fer-tilization (IVF): why doing it in unstimulated cycles?. Gynecol Ob-stet Fertil 2007; 35(9): 877-80.
140. Lédée-Bataille N, Dubanchet S, Kadoch J, Castelo-Branco A, Frydman R, Chaouat G. Controlled natural in vitro fertilizationmay be an alternative for patients with repeated unexplained im-plantation failure and a high uterine natural killer cell count. FertilSteril 2004; 82(1): 234-6.
141. Croy BA, Ashkar AA, Minhas K, Greenwood JD. Can murine uter-ine natural killer cells give insights into the pathogenesis ofpreeclampsia? J Soc Gynecol Investig 2000; 7(1): 12-20.
142. Horcajadas JA, Riesewijk A, Polman J, et al. Effect of controlledovarian hyperstimulation in IVF on endometrial gene expressionprofiles. Mol Hum Reprod 2005; 11(3): 195-205.
143. Haouzi D, Mahmoud K, Fourar M, et al. Identification of newbiomarkers of human endometrial receptivity in the natural cycle. Hum Reprod 2009; 24(1): 198-205.
144. Di Simone N, Meroni PL, de Papa N, et al. Antiphospholipid anti-bodies affect trophoblast gonadotropin secretion and invasivenessby binding directly and through adhered beta2-glycoprotein I. Ar-thritis Rheum 2000; 43(1): 140-50.
145. Kutteh WH. Antiphospholipid antibodies and reproduction. J Re-prod Immunol 1997; 35(2): 151-71.
146. Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE. Complement activation induces dysregulation of angiogenic fac-tors and causes fetal rejection and growth restriction. J Exp Med 2006; 203(9): 2165-75.
147. el-Roeiy A, Gleicher N, Friberg J, Confino E, Dudkiewicz A. Cor-relation between peripheral blood and follicular fluid autoantibod-ies and impact on in vitro fertilization. Obstet Gynecol 1987; 70(2):163-70.
148. Buckingham KL, Stone PR, Smith JF, Chamley LW. Antiphos-pholipid antibodies in serum and follicular fluid--is there a correla-tion with IVF implantation failure? Hum Reprod 2006; 21(3): 728-34.
149. Matsubayashi H, Sugi T, Arai T, et al. IgG-antiphospholipid anti-bodies in follicular fluid of IVF-ET patients are related to low fer-tilization rate of their oocytes. Am J Reprod Immunol 2006; 55(5):341-8.
150. Choudhury SR, Knapp LA. Human reproductive failure I: immu-nological factors. Hum Reprod Update 2001; 7(2): 113-34.
151. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies(ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335(8705): 1544-7.
152. Meroni PL, Gerosa M, Raschi E, Scurati S, Grossi C, Borghi MO. Updating on the pathogenic mechanisms 5 of the antiphos-pholipid antibodies-associated pregnancy loss. Clin Rev AllergyImmunol 2008; 34(3): 332-7.
153. Stern C, Chamley L, Hale L, Kloss M, Speirs A, Baker HW. Anti-bodies to beta2 glycoprotein I are associated with in vitro fertiliza-tion implantation failure as well as recurrent miscarriage: results ofa prevalence study. Fertil Steril 1998; 70(5): 938-44.
154. Birkenfeld A, Mukaida T, Minichiello L, Jackson M, Kase NG, Yemini M. Incidence of autoimmune antibodies in failed embryotransfer cycles. Am J Reprod Immunol 1994; 31(2-3): 65-8.
155. Gleicher N, Liu HC, Dudkiewicz A, et al. Autoantibody profilesand immunoglobulin levels as predictors of in vitro fertilizationsuccess. Am J Obstet Gynecol 1994; 170(4): 1145-9.
156. Coulam CB, Kaider BD, Kaider AS, Janowicz P, Roussev RG. Antiphospholipid antibodies associated with implantationfailure after IVF/ET. J Assist Reprod Genet 1997; 14(10): 603-8.
157. Denis AL, Guido M, Adler RD, Bergh PA, Brenner C, Scott RT Jr. Antiphospholipid antibodies and pregnancy rates and outcome in invitro fertilization patients. Fertil Steril 1997; 67(6): 1084-90.
158. Geva E, Yaron Y, Lessing JB, et al. Circulating autoimmuneantibodies may be responsible for implantation failure in in vitro fertilization. Fertil Steril 1994; 62(4): 802-6.
159. Kowalik A, Vichnin M, Liu HC, Branch W, Berkeley AS. Midfol-licular anticardiolipin and antiphosphatidylserine antibody titers donot correlate with in vitro fertilization outcome. Fertil Steril 1997; 68(2): 298-304.
160. Hill JA, Choi BC. Maternal immunological aspects of pregnancysuccess and failure. J Reprod Fertil Suppl 2000; 55: 91-7.
161. Hornstein MD, Davis OK, Massey JB, Paulson RJ, Collins JA. Antiphospholipid antibodies and in vitro fertilization success: ameta-analysis. Fertil Steril 2000; 73(2): 330-3.
162. Gleicher N, Vidali A, Karande V. The immunological Wars of theRoses: disagreements amongst reproductive immunologists. HumReprod 2002; 17(3): 539-42.
163. Matsubayashi H, Arai T, Izumi S, Sugi T, McIntyre JA, Makino T. Anti-annexin V antibodies in patients with early pregnancy loss orimplantation failures. Fertil Steril 2001; 76(4): 694-9.
164. Eldar-Geva T, Wood C, Lolatgis N, et al. Cumulative pregnancyand live birth rates in women with antiphospholipid antibodies un-dergoing assisted reproduction. Hum Reprod 1999; 14(6): 1461-6.
165. Practice Committee of American Society for Reproductive Medicine. Anti-phospholipid antibodies do not affect IVF success. FertilSteril 2008; 90(5 Suppl): S172-3.
166. Ermel LD, Marshburn PB, Kutteh WH. Interaction of heparin withantiphospholipid antibodies (APA) from the sera of women withrecurrent pregnancy loss (RPL). Am J Reprod Immunol 1995; 33(1): 14-20.
167. Kutteh WH. Antiphospholipid antibody-associated recurrent preg-nancy loss: treatment with heparin and low-dose aspirin is superiorto low-dose aspirin alone. Am J Obstet Gynecol 1996; 174(5):1584-9.
168. Kutteh WH, Yetman DL, Chantilis SJ, Crain J. Effect of antiphos-pholipid antibodies in women undergoing in-vitro fertilization: roleof heparin and aspirin. Hum Reprod 1997; 12(6): 1171-5.
169. Stern C, Chamley L, Norris H, Hale L, Baker HW. A randomized,double-blind, placebo-controlled trial of heparin and aspirin forwomen with in vitro fertilization implantation failure and antiphos-pholipid or antinuclear antibodies. Fertil Steril 2003; 80(2): 376-83.
170. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrentmiscarriage for women with antiphospholipid antibody or lupus an-ticoagulant. Cochrane Database Syst Rev 2005; (2): CD002859.
171. Vaquero E, Lazzarin N, Valensise Het, et al. Pregnancy outcome inrecurrent spontaneous abortion associated with antiphospholipidantibodies: a comparative study of intravenous immunoglobulinversus prednisone plus low-dose aspirin. Am J Reprod Immunol 2001; 45(3): 174-9.
172. Triolo G, Ferrante A, Ciccia F, et al. Randomized study of subcu-taneous low molecular weight heparin plus aspirin versus intrave-nous immunoglobulin in the treatment of recurrent fetal loss asso-ciated with antiphospholipid antibodies. Arthritis Rheum 2003; 48(3): 728-31.
173. Dendrinos S, Sakkas E, Makrakis E. Low-molecular-weight hepa-rin versus intravenous immunoglobulin for recurrent abortion asso-ciated with antiphospholipid antibody syndrome. Int J GynaecolObstet 2009; 104(3): 223-5.
174. Clark AL, Branch DW, Silver RM, Harris EN, Pierangeli S, Spin-nato JA. Pregnancy complicated by the antiphospholipid syndrome:outcomes with intravenous immunoglobulin therapy. Obstet Gyne-col 1999; 93(3): 437-41.
175. Wong RC, Favaloro EJ. Clinical features, diagnosis, and manage-ment of the antiphospholipid syndrome. Semin Thromb Hemost 2008; 34(3): 295-304.
176. Takeshita T. Diagnosis and treatment of recurrent miscarriageassociated with immunologic disorders: Is paternal lymphocyteimmunization a relic of the past? J Nippon Med Sch 2004; 71(5):308-13.
177. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectionalcytokine interactions in the maternal-fetal relationship: is success-ful pregnancy a TH2 phenomenon? Immunol Today 1993; 14(7):353-6.
178. Lédée-Bataille N, Bonnet-Chea K, Hosny G, Dubanchet S, Frydman R, Chaouat G. Role of the endometrial tripod interleukin-18, -15, and -12 in inadequate uterine receptivity in patients with ahistory of repeated in vitro fertilization-embryo transfer failure. Fertil Steril 2005; 83(3): 598-605.
179. Quenby S, Farquharson R. Uterine natural killer cells, implantationfailure and recurrent miscarriage. Reprod Biomed Online 2006; 13(1): 24-8.
180. Lachapelle MH, Miron P, Hemmings R, Roy DC. Endometrial T,B, and NK cells in patients with recurrent spontaneous abortion.Altered profile and pregnancy outcome. J Immunol 1996; 156(10):4027-34.
181. Ntrivalas EI, Kwak-Kim JY, Gilman-Sachs A, et al. Status of pe-ripheral blood natural killer cells in women with recurrent sponta-neous abortions and infertility of unknown aetiology. Hum Reprod 2001; 16(5): 855-61.
182. Kwak JY, Beaman KD, Gilman-Sachs A, Ruiz JE, Schewitz D, Beer AE. Up-regulated expression of CD56+, CD56+/CD16+, andCD19+ cells in peripheral blood lymphocytes in pregnant womenwith recurrent pregnancy losses. Am J Reprod Immunol 1995; 34(2): 93-9.
183. Yamada H, Kato EH, Kobashi G, et al. High NK cell activity inearly pregnancy correlates with subsequent abortion with normalchromosomes in women with recurrent abortion. Am J ReprodImmunol 2001; 46(2): 132-6.
184. Yamamoto T, Takahashi Y, Kase N, Mori H. Role of decidualnatural killer (NK) cells in patients with missed abortion: differ-ences between cases with normal and abnormal chromosome. ClinExp Immunol 1999; 116(3): 449-52.
185. Quack KC, Vassiliadou N, Pudney J, Anderson DJ, Hill JA. Leu-kocyte activation in the decidua of chromosomally normal and ab-normal fetuses from women with recurrent abortion. Hum Reprod 2001; 16(5): 949-55.
186. Lédée-Bataille N, Laprée-Delage G, Taupin JL, Dubanchet S, Frydman R, Chaouat G. Concentration of leukaemia inhibitory fac-tor (LIF) in uterine flushing fluid is highly predictive of embryoimplantation. Hum Reprod 2002; 17(1):213-8.
187. Kwak-Kim JY, Chung-Bang HS, Ng SC, et al. Increased T helper 1cytokine responses by circulating T cells are present in women withrecurrent pregnancy losses and in infertile women with multipleimplantation failures after IVF. Hum Reprod 2003; 18(4): 767-73.
188. Ng SC, Gilman-Sachs A, Thaker P, Beaman KD, Beer AE, Kwak-Kim J. Expression of intracellular Th1 and Th2 cytokines inwomen with recurrent spontaneous abortion, implantation failuresafter IVF/ET or normal pregnancy. Am J Reprod Immunol 2002; 48(2): 77-86.
189. Lim KJ, Odukoya OA, Ajjan RA, Li TC, Weetman AP, Cooke ID. The role of T-helper cytokines in human reproduction. Fertil Steril 2000; 73(1): 136-42.
190. Hill JA, Polgar K, Anderson DJ. T-helper 1-type immunity to tro-phoblast in women with recurrent spontaneous abortion. JAMA 1995; 273(24): 1933-6.
191. Piccinni MP, Beloni L, Livi C, Maggi E, Scarselli G, Romagnani S. Defective production of both leukemia inhibitory factor and type 2T-helper cytokines by decidual T cells in unexplained recurrentabortions. Nat Med 1998; 4(9): 1020-4.
192. Bates MD, Quenby S, Takakuwa K, Johnson PM, Vince GS. Aber-rant cytokine production by peripheral blood mononuclear cells inrecurrent pregnancy loss? Hum Reprod 2002; 17(9): 2439-44.
193. Kruse C, Varming K, Christiansen OB. Prospective, serial investi-gations of in-vitro lymphocyte cytokine production, CD62L ex-pression and proliferative response to microbial antigens in womenwith recurrent miscarriage. Hum Reprod 2003; 18(11): 2465-72.
194. Borzychowski AM, Croy BA, Chan WL, Redman CW, Sargent IL. Changes in systemic type 1 and type 2 immunity in normal preg-nancy and pre-eclampsia may be mediated by natural killer cells. Eur J Immunol 2005; 35(10): 3054-63.
195. Chaouat G, Ledée-Bataille N, Dubanchet S, Zourbas S, Sandra O, Martal J. TH1/TH2 paradigm in pregnancy: paradigm lost? Cytoki-nes in pregnancy/early abortion: reexamining the TH1/TH2 para-digm. Int Arch Allergy Immunol 2004; 134(2): 93-119.
196. Steck T, Giess R, Suetterlin MW, et al. Leukaemia inhibitory factor(LIF) gene mutations in women with unexplained infertility and re-current failure of implantation after IVF and embryo transfer. Eur JObstet Gynecol Reprod Biol 2004; 112(1): 69-73.
197. Jack DL, Read RC, Tenner AJ, Frosch M, Turner MW, Klein NJ. Mannose-binding lectin regulates the inflammatory response ofhuman professional phagocytes to Neisseria meningitidis serogroupB. J Infect Dis 2001; 184(9): 1152-62.
198. Kilpatrick DC, Bevan BH, Liston WA. Association between man-nan binding protein deficiency and recurrent miscarriage. Hum Re-prod 1995; 10(9): 2501-5.
199. Dahl M, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. Mor-bidity and mortality in persons with mannose-binding lectin defi-ciency. The Osterbro study. Ugeskr Laeger 2004; 166(50): 4606-9.
200. Kruse C, Rosgaard A, Steffensen R, Varming K, Jensenius JC, Christiansen OB. Low serum level of mannan-binding lectin is adeterminant for pregnancy outcome in women with recurrent spon-taneous abortion. Am J Obstet Gynecol 2002; 187(5): 1313-20.
201. Shetty S, Ghosh K. Anti-phospholipid antibodies and other immu-nological causes of recurrent foetal loss--a review of literature ofvarious therapeutic protocols. Am J Reprod Immunol 2009; 62(1):9-24.
202. Morikawa M, Yamada H, Kato EH, et al. Massive intravenousimmunoglobulin treatment in women with four or more recurrentspontaneous abortions of unexplained etiology: down-regulation ofNK cell activity and subsets. Am J Reprod Immunol 2001; 46(6):399-404.
203. Clark DA, Chaouat G. Loss of surface CD200 on stored allogeneicleukocytes may impair anti-abortive effect in vivo. Am J ReprodImmunol 2005; 53(1): 13-20.
204. Gorczynski RM. Thymocyte/splenocyte-derived CD4+CD25+Tregstimulated by anti-CD200R2 derived dendritic cells suppress mixedleukocyte cultures and skin graft rejection. Transplantation 2006; 81(7): 1027-34.
205. Wright GJ, Cherwinski H, Foster-Cuevas M, et al. Characterizationof the CD200 receptor family in mice and humans and their inter-actions with CD200. J Immunol 2003; 171(6): 3034-46.
206. Daya S, Gunby J, Porter F, Scott J, Clark DA. Critical analysis ofintravenous immunoglobulin therapy for recurrent miscarriage. Hum Reprod Update 1999; 5(5): 475-82.
207. Stephenson MD, Dreher K, Houlihan E, Wu V. Prevention of un-explained recurrent spontaneous abortion using intravenous immu-noglobulin: a prospective, randomized, double-blinded, placebo-controlled trial. Am J Reprod Immunol 1998; 39(2): 82-8.
208. Coulam CB, Krysa L, Stern JJ, Bustillo M. Intravenous immuno-globulin for treatment of recurrent pregnancy loss. Am J ReprodImmunol 1995; 34(6): 333-7.
209. Christiansen OB, Pedersen B, Rosgaard A, Husth M. A randomized,double-blind, placebo-controlled trial of intravenous immunoglobu-lin in the prevention of recurrent miscarriage: evidence for a thera-peutic effect in women with secondary recurrent miscarriage. HumReprod 2002; 17(3): 809-16.
210. Hutton B, Sharma R, Fergusson D, et al. Use of intravenous immu-noglobulin for treatment of recurrent miscarriage: a systematic re-view. BJOG 2007; 114(2): 134-42.
211. Clark DA, Coulam CB, Stricker RB. Is intravenous immunoglobu-lins (IVIG) efficacious in early pregnancy failure? A critical reviewand meta-analysis for patients who fail in vitro fertilization andembryo transfer (IVF). J Assist Reprod Genet 2006, 23(1): 1-13.
212. Carp HJ. Intravenous immunoglobulin: effect on infertility andrecurrent pregnancy loss. Isr Med Assoc J 2007; 9(12): 877-80.
213. van den Heuvel MJ, Peralta CG, Hatta K, Han VK, Clark DA. Decline in number of elevated blood CD3(+) CD56(+) NKT cellsin response to intravenous immunoglobulin treatment correlateswith successful pregnancy. Am J Reprod Immunol 2007; 58(5):447-59.
214. Winger EE, Reed JL, Ashoush S, Ahuja S, El-Toukhy T, Taranissi M. Treatment with adalimumab (Humira) and intravenous immu-noglobulin improves pregnancy rates in women undergoing IVF. Am J Reprod Immunol 2009; 61(2): 113-20.
215. Porter TF, LaCoursiere Y, Scott JR. Immunotherapy for recurrentmiscarriage. Cochrane Database Syst Rev 2006; (2): CD000112.
216. Pandey MK, Rani R, Agrawal S. An update in recurrent spontane-ous abortion. Arch Gynecol Obstet 2005; 272(2): 95-108.
217. McIntyre JA, Coulam CB, Faulk WP. Recurrent spontaneous abor-tion. Am J Reprod Immunol 1989; 21(3-4): 100-4.
218. Tamura M, Takakuwa K, Arakawa M, Yasuda M, Kazama Y, Tanaka K. Relationship between MLR blocking antibodies and theoutcome of the third pregnancy in patients with two consecutivespontaneous abortions. J Perinat Med 1998; 26(1): 49-53.
219. Daya S, Gunby J. The effectiveness of allogeneic leukocyte immu-nization in unexplained primary recurrent spontaneous abortion.Recurrent Miscarriage Immunotherapy Trialists Group. Am J Re-prod Immunol 1994; 32(4): 294-302.
220. Pandey MK, Thakur S, Agrawal S. Lymphocyte immunotherapyand its probable mechanism in the maintenance of pregnancy inwomen with recurrent spontaneous abortion. Arch Gynecol Obstet 2004; 269(3): 161-72.
221. Gatenby PA, Cameron K, Simes RJ, et al. Treatment of recurrentspontaneous abortion by immunization with paternal lymphocytes:results of a controlled trial. Am J Reprod Immunol 1993; 29(2): 88-94.
222. Mowbray JF, Gibbings C, Liddell H, et al. Controlled trial oftreatment of recurrent spontaneous abortion by immunisation withpaternal cells. Lancet 1985; 1(8435): 941-3.
223. Worldwide collaborative observational study and meta-analysis onallogenic leukocyte immunotherapy for recurrent spontaneousabortion. Recurrent Miscarriage Immunotherapy Trialists Group. Am J Reprod Immunol 1994; 32(2): 55-72.
224. Kling C, Steinmann J, Westphal E, Magez J, Kabelitz D. Experi-ence with allogeneic leukocyte immunization for implantationfailure in the in-vitro fertilization program. Am J Reprod Immunol 2002; 48: 147.
225. Ober C, Karrison T, Odem RR, et al. Mononuclear-cell immunisa-tion in prevention of recurrent miscarriages: a randomised trial. Lancet 1999; 354(9176): 365-9.
226. Clark DA, Chaouat G. Immunomodulation by CD200 as a basisfor prevention of cytokine-dependent fetal loss syndrome. Am JReprod Immunol 2003; 49: 350-1.
227. Research, C.f.B.E.a., Lymphocyte Immune Therapy. 2001.
228. Kling C, Steinmann J, Westphal E, Magez J, Kabelitz D. Adverseeffects of intradermal allogeneic lymphocyte immunotherapy: acutereactions and role of autoimmunity. Hum Reprod 2006; 21(2): 429-35.
229. Pearlman SA, Meek RS, Cowchock FS, Smith JB, McFarland J, Aster RH. Neonatal alloimmune thrombocytopenia after maternalimmunization with paternal mononuclear cells: successful treat-ment with intravenous gamma globulin. Am J Perinatol 992; 9(5-6): 448-51.